Several biopharmaceuticals are presently in the late developmental stage and their imminent approval could see a wave of new products enter the market. These bio pharmaceuticals include sterile injectables and oncology products, which are the largest product segments among biopharmaceuticals. With biopharmaceutical companies looking to narrow their focus to research and development, there is likely to be an increased demand for higher manufacturing capacity in sterile vials and syringes. Although the manufacture of injectables presently constitutes the smallest segment in the pharmaceutical contract manufacturing markets, the increased demand for sterile products, especially injectables, is expected to drive the this segment across the globe.
The underlying cost of building new manufacturing plants across regional boundaries as well as complying with differing regulatory environments and requirements are encouraging the outsourcing of manufacturing and related processes among pharmaceutical and biopharmaceutical companies. "While North America is the market leader in terms of revenue share, followed by Europe, it is Asia that is expected to show strong growth due to the huge manufacturing capacity available in the region," says the analyst. "Among the dosage forms, solid dosage forms are continuing to lead revenue contribution, whereas liquid dosage forms are expected to lose their market share to injectables that primarily include sterile products and biopharmaceuticals (primarily oncology)."
Tidak ada komentar:
Posting Komentar